BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38160001)

  • 1. Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study.
    Kim JH; Cha Y; Shin SJ; Park YS; Kang JH; Kim C; Lim SH; Kang MJ; Kim JG; Hwang IG; Choi JK; Shin SH; Kang SY; Lee SC; Lim ST; Kim JS; Jeung HC; Kang MH; Choi IS; Ryu HW; Lee KH; Lee MH; Lee JY; Park JH; Jeon SY; Lee N; Park CY; Kim YH
    Anticancer Res; 2024 Jan; 44(1):347-359. PubMed ID: 38160001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
    Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer.
    Price T; Shen L; Ma B; Esser R; Chen W; Gibbs P; Lim R; Cheng AL
    Asia Pac J Clin Oncol; 2019 Aug; 15(4):225-230. PubMed ID: 31090260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective analysis on first-line bevacizumab, cetuximab, and panitimumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG).
    Degirmencioglu S; Tanriverdi O; Menekse S; Dogan M; Hacıoglu B; Oktay E; Erdem D; Arpaci E; Uluc BO; Turhal S; Yilmaz M; Pilanci KN; Sakin A; Araz M; Cokmert S; Ozdemir O; Sen E; Nayir E
    J BUON; 2019; 24(1):136-142. PubMed ID: 30941962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Miller-Phillips L; Modest DP; Jung A; Kirchner T; Stintzing S
    Br J Cancer; 2021 Feb; 124(3):587-594. PubMed ID: 33154570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
    Fischer LE; Stintzing S; von Weikersthal LF; Modest DP; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Giessen-Jung C; Uhlig J; Peuser B; Denzlinger C; Stahler A; Weiss L; Heinrich K; Held S; Jung A; Kirchner T; Heinemann V
    Br J Cancer; 2022 Sep; 127(5):836-843. PubMed ID: 35637412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group.
    Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA;
    Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
    Stintzing S; Modest DP; Rossius L; Lerch MM; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Giessen-Jung C; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V;
    Lancet Oncol; 2016 Oct; 17(10):1426-1434. PubMed ID: 27575024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in
    Qin S; Liu T; Xu J; Li Q; Cheng Y; Zhang A; Esser R; Chang H; Li J
    Future Oncol; 2023 May; 19(15):1053-1061. PubMed ID: 37017100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
    Parisi A; Porzio G; Cannita K; Venditti O; Avallone A; Filippi R; Salvatore L; Tortora G; Ribelli M; Nigro O; Gelsomino F; Spallanzani A; Zurlo V; Leo S; Dell'Aquila E; Claudia F; Lombardi P; Keränen SR; Aimar G; Depetris I; Giampieri R; Morelli C; De Tursi M; Tinari N; Di Pietro FR; De Galitiis F; Zanaletti N; Troiani T; Vitale P; Garajova I; Ghidini M; Spinelli GP; Zoratto F; Roberto M; Ierino D; Petrillo A; D'Orazio C; Ficorella C; Cortellini A
    Clin Colorectal Cancer; 2021 Dec; 20(4):318-325. PubMed ID: 34380594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAF
    Kang S; Lee MW; Song IC; Lee HJ; Yun HJ; Jo DY; Kim JS; Kwon JH; Kim JY; Lee KH; Ryu H
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7819-7829. PubMed ID: 37031435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.
    Han J; Xiao D; Tan C; Zeng X; Hu H; Zeng S; Jiang Q; She L; Yao L; Li L; Tang L; Ma J; Huang J; Shen L
    Cancer Control; 2020; 27(1):1073274820902271. PubMed ID: 32107929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.
    Tejpar S; Stintzing S; Ciardiello F; Tabernero J; Van Cutsem E; Beier F; Esser R; Lenz HJ; Heinemann V
    JAMA Oncol; 2017 Feb; 3(2):194-201. PubMed ID: 27722750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
    JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Yoshino T; Hooda N; Younan D; Muro K; Shitara K; Heinemann V; O'neil BH; Herrero FR; Peeters M; Soeda J; Suh M; Reichert H; Mezzi K; Fryzek J; Chia V; Rehn M; Stintzing S
    Eur J Cancer; 2024 May; 202():113975. PubMed ID: 38442645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
    Sastre J; García-Alfonso P; Viéitez JM; Cano MT; Rivera F; Reina-Zoilo JJ; Salud-Salvia A; Quintero G; Robles-Díaz L; Safont MJ; La Casta A; Gil S; Polo E; Asensio-Martínez E; García-Paredes B; López RL; Guillot M; Valladares-Ayerbes M; Aranda E; Díaz-Rubio E;
    ESMO Open; 2021 Apr; 6(2):100062. PubMed ID: 33711671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.
    Burge M; Semira C; Lee B; Lee M; Kosmider S; Wong R; Shapiro J; Ma B; Dean AP; Zimet AS; Steel SA; Lok SW; Torres J; Eastgate M; Wong HL; Gibbs P
    Clin Colorectal Cancer; 2018 Sep; 17(3):e593-e599. PubMed ID: 29958812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.
    Liang YH; Chen KH; Shao YY
    Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
    Satake H; Ando K; Oki E; Shimokawa M; Makiyama A; Saeki H; Tsuji A; Mori M
    BMC Cancer; 2020 Nov; 20(1):1116. PubMed ID: 33203393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
    Rossini D; Boccaccino A; Carullo M; Antoniotti C; Dima G; Ciracì P; Marmorino F; Moretto R; Masi G; Cremolini C
    Eur J Cancer; 2023 May; 184():106-116. PubMed ID: 36913832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.